Research Evidence
Pediatric Growth Hormone Deficiency
The clinical data supporting sermorelin's efficacy in children is the most robust. In the pivotal studies supporting Geref's FDA approval, daily subcutaneous sermorelin increased growth velocity in 74% of children with idiopathic GHD after 6 months of treatment. Significant increases in height velocity were sustained during 12 months of treatment, with limited data suggesting maintained efficacy through 36 months of continuous therapy. Sermorelin induced catch-up growth in the majority of GH-deficient children, with the best responses in shorter children with delayed bone age.
Elderly Adults and Age-Related GH Decline
Vittone et al. (1997) conducted a 6-week study in 11 healthy men aged 64 to 76 years, administering 2 mg of subcutaneous sermorelin nightly. The study demonstrated a near-doubling of nocturnal GH output, though IGF-1 levels did not significantly increase over the short treatment period. In a separate, longer study of 19 adults aged 55 to 71, a 16-week randomized placebo-controlled trial demonstrated significant increases in nocturnal GH secretion and serum IGF-1 in both men and women. Men showed a significant increase in lean body mass (1.26 kg) and improved insulin sensitivity, while both sexes exhibited increased skin thickness.
A 6-month study combining daily bedtime sermorelin with exercise conditioning demonstrated IGF-1 increases of approximately 35% and favorable changes in body composition, including increased lean mass and decreased visceral abdominal fat.GH Stimulation Testing
Sermorelin has established utility as a diagnostic agent. Intravenous administration of sermorelin (1 mcg/kg) provides a rapid, relatively specific test for diagnosing GH deficiency, with fewer false-positive responses compared to other provocative tests such as insulin tolerance testing. This diagnostic application was part of its original FDA approval.
Limitations of the Evidence Base
While sermorelin's mechanism and acute GH-releasing effects are well characterized, several limitations should be acknowledged. The largest body of controlled human data comes from pediatric GHD populations, a different clinical context from adult anti-aging use. Adult studies have generally been small (fewer than 20 participants), short in duration (4 to 6 months), and focused on surrogate markers (IGF-1, body composition) rather than hard clinical endpoints. Large-scale, long-term randomized controlled trials in adults using current compounded sermorelin formulations are lacking.